Mineralys Therapeutics, Inc.
MLYSAs of the close on Sep 25, 2026
Price
$25.86
Market cap
$2.29B
P/E (diluted TTM)
—
A per-share figure for one of the last four quarters is not shown, so no four-quarter total is given
EPS (TTM)
—
A per-share figure for one of the last four quarters is not shown, so no four-quarter total is given
Dividend yield
—
Dividend records do not yet cover the latest payments
Figures shown here come from public SEC filings. Dates beside each section show the available history.
How Mineralys Therapeutics, Inc. Makes Money
No flow chart is shown because the available revenue and expense lines do not reconcile exactly. The reported financial history below remains available.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 4 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 30, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| Candriam S.C.A. | 2026-03-31 | 801,904 | $21.7M | SEC filing |
| SMA Capital LLC | 2026-03-31 | 208 | $5.64K | SEC filing |
| SBI Securities Co., Ltd. | 2026-03-31 | 117 | $3.17K | SEC filing |
| MetLife Investment Management, LLC | 2026-03-31 | 26,826 | $727K | SEC filing |
| CWM, LLC | 2026-03-31 | 6,051 | $164K | SEC filing |
| Larson Financial Group LLC | 2026-03-31 | 6 | $163 | SEC filing |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 2026-03-31 | 1,538,662 | $41.7M | SEC filing |
| Rockefeller Capital Management L.P. | 2026-03-31 | 555 | $15K | SEC filing |
| AMERIPRISE FINANCIAL INC | 2026-03-31 | 221,305 | $6M | SEC filing |
| AMERICAN CENTURY COMPANIES INC | 2026-03-31 | 884,107 | $24M | SEC filing |
| RENAISSANCE TECHNOLOGIES LLC | 2026-03-31 | 382,800 | $10.4M | SEC filing |
| Parkman Healthcare Partners LLC | 2026-03-31 | 380,137 | $10.3M | SEC filing |
| Optiver Holding B.V. | 2026-03-31 | 80 | $2.17K | SEC filing |
| LOS ANGELES CAPITAL MANAGEMENT LLC | 2026-03-31 | 46,835 | $1.27M | SEC filing |
| Clearstead Advisors, LLC | 2026-03-31 | 11 | $298 | SEC filing |
| VICTORY CAPITAL MANAGEMENT INC | 2026-03-31 | 33,141 | $898K | SEC filing |
| Nuveen, LLC | 2026-03-31 | 112,007 | $3.03M | SEC filing |
| IFP Advisors, Inc | 2026-03-31 | 1 | $27 | SEC filing |
| Universal- Beteiligungs- und Servicegesellschaft mbH | 2026-03-31 | 19,689 | $533K | SEC filing |
| GF FUND MANAGEMENT CO. LTD. | 2026-03-31 | 1,777 | $48.1K | SEC filing |
120 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Mineralys Therapeutics, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-06-30 · Congleton Jon: Larger than 86 of the 91 other insider sales of Common Stock on file. SEC filing
- 2026-06-26 · Warren Eric: Larger than 88 of the 91 other insider sales of Common Stock on file. SEC filing
- 2026-03-31 · Congleton Jon: Larger than 85 of the 91 other insider sales of Common Stock on file. SEC filing
- 2026-01-05 · Rodman David Malcom: Larger than 84 of the 91 other insider sales of Common Stock on file. SEC filing
- 2026-01-05 · Rodman David Malcom: Larger than 90 of the 91 other insider sales of Common Stock on file. SEC filing
- 2026-01-02 · Rodman David Malcom: Larger than 87 of the 91 other insider sales of Common Stock on file. SEC filing
- 2025-11-20 · Slingsby Brian Taylor: Larger than all 91 other insider sales of Common Stock on file. SEC filing
- 2025-11-11 · Congleton Jon: Larger than 89 of the 91 other insider sales of Common Stock on file. SEC filing
- 2025-11-11 · Levy Adam Scott: Larger than 82 of the 91 other insider sales of Common Stock on file. SEC filing
- 2025-07-30 · Levy Adam Scott: Larger than 83 of the 91 other insider sales of Common Stock on file. SEC filing
Independent insiders buying near the same time
- 2025-09-04–2025-09-04: 2 event(s) across 2 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing )
- 2025-03-13–2025-03-13: 4 event(s) across 4 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing , filing )
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-06-30 | Congleton Jon · Chief Executive Officer | Common Stock | S — Open market or private sale | −58,000 | 25.94 | SEC filing |
| 2026-06-30 | Congleton Jon · Chief Executive Officer | Common Stock | S — Open market or private sale | −17,000 | 26.82 | SEC filing |
| 2026-06-26 | Warren Eric · Chief Commercial Officer | Common Stock | S — Open market or private sale | −104,124 | 25.90 | SEC filing |
| 2026-06-17 | Karydas Daphne · Director | Common Stock | S — Open market or private sale | −3,000 | 25.00 | SEC filing |
| 2026-06-17 | Rodman David Malcom · Chief Medical Officer | Common Stock | S — Open market or private sale | −4,584 | 25.00 | SEC filing |
| 2026-06-15 | Rodman David Malcom · Chief Medical Officer | Common Stock | S — Open market or private sale | −9,890 | 23.81 | SEC filing |
| 2026-06-12 | Rodman David Malcom · Chief Medical Officer | Common Stock | S — Open market or private sale | −6,349 | 23.93 | SEC filing |
| 2026-06-10 | Rodman David Malcom · Chief Medical Officer | Common Stock | S — Open market or private sale | −2,170 | 25.00 | SEC filing |
Showing 8 of 18 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-26 | Warren Eric · Chief Commercial Officer | Common Stock | M — Exercise or conversion of derivative security | +104,124 | SEC filing |
| 2026-06-26 | Warren Eric · Chief Commercial Officer | Stock Option | M — Exercise or conversion of derivative security | −104,124 | SEC filing |
| 2026-06-17 | Karydas Daphne · Director | Common Stock | M — Exercise or conversion of derivative security | +3,000 | SEC filing |
| 2026-06-17 | Rodman David Malcom · Chief Medical Officer | Common Stock | M — Exercise or conversion of derivative security | +417 | SEC filing |
| 2026-06-17 | Rodman David Malcom · Chief Medical Officer | Common Stock | M — Exercise or conversion of derivative security | +4,167 | SEC filing |
| 2026-06-17 | Rodman David Malcom · Chief Medical Officer | Stock Option | M — Exercise or conversion of derivative security | −4,167 | SEC filing |
| 2026-06-17 | Karydas Daphne · Director | Stock Option | M — Exercise or conversion of derivative security | −3,000 | SEC filing |
| 2026-06-17 | Rodman David Malcom · Chief Medical Officer | Stock Option | M — Exercise or conversion of derivative security | −417 | SEC filing |
Showing 8 of 20 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-02-19 | Slingsby Brian Taylor · Director, 10% owner | Common Stock | J — Other acquisition or disposition | +6,200 | SEC filing |
| 2026-02-19 | Slingsby Brian Taylor · Director, 10% owner | Common Stock | J — Other acquisition or disposition | −6,200 | SEC filing |
| 2026-02-19 | Slingsby Brian Taylor · Director, 10% owner | Stock Option | J — Other acquisition or disposition | −8,300 | SEC filing |
| 2026-02-19 | Slingsby Brian Taylor · Director, 10% owner | Stock Option | J — Other acquisition or disposition | +8,300 | SEC filing |
| 2025-02-13 | Slingsby Brian Taylor · Director, 10% owner | Stock Option | J — Other acquisition or disposition | −32,900 | SEC filing |
Showing 5 of 5 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.